Serplulimab Plus Chemotherapy As First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
FRONTIERS IN IMMUNOLOGY（2023）
Key words
extensive-stage small-cell lung cancer,serplulimab,etoposide and carboplatin,quality-adjusted life-years,incremental cost-effectiveness ratios
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined